A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Assessment of PD-L1 expression in patients with urothelial cancer with contraindications to platinum based therapy
Background. Urothelial cancer ranks 7th and 17th of all the malignant tumors in males and females, respectively. Development of new immunotherapeutic drugs provides new possibilities in treatment of such patients, especially the patient population in whom platinum‑based therapy is contraindicated. Administration of immunooncology drugs requires determination of PD-L1, for which various diagnostic systems are used. The question regarding correlation of results of determination of PD-L1doi:10.18027/2224-5057-2019-9-1-10-15 fatcat:vmpwzulj35fpxg64vla7cwzr7q